The present invention relates to a viral vector for expression of the cell death-inducing PUMA protein, for use in gene therapy, for example for the treatment of rheumatoid arthritis. This vector consists in particular of a recombinant adenovirus expressing the gene encoding the PUMA protein and of a recombinant baculovirus containing a coxsackie-adenovirus receptor (CAR).

The present invention relates to a recombinant baculovirus comprising: (a) a nucleotide sequence encoding a foreign virus envelope protein; (b) a first promoter operatively linked to the envelope-encoding nucleotide sequence; (c) a nucleotide sequence encoding an antigen protein; and (d) a second promoter operatively linked to the antigen-encoding nucleotide sequence; and a vaccine composition using the same. The recombinant baculovirus of the present invention has an excellent efficacy on both humoral and cellular immune responses against a specific antigen (e.g., HPV L1), enabling to function as a more efficient DNA vaccine.